Compare TCX & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCX | KRRO |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.0M | 150.0M |
| IPO Year | 2005 | 2019 |
| Metric | TCX | KRRO |
|---|---|---|
| Price | $13.33 | $12.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $34.80 |
| AVG Volume (30 Days) | 19.5K | ★ 120.7K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $362,275,000.00 | $6,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 6.76 | ★ 181.46 |
| 52 Week Low | $12.95 | $5.20 |
| 52 Week High | $25.17 | $55.89 |
| Indicator | TCX | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 35.67 | 54.16 |
| Support Level | $13.00 | $9.51 |
| Resistance Level | $15.29 | $12.54 |
| Average True Range (ATR) | 0.64 | 1.07 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 19.40 | 51.87 |
Tucows Inc is a corporate parent, allocating capital and providing efficient shared services to its three businesses. The Company offers Mobile Service Enabler (MSE) solutions, as well as professional services to other retail mobile providers. The Company is also a distributor of Internet services, including domain name registration, digital certificates, and email. It provides these services through an Internet-based distribution network of Internet Service Providers, web hosting companies, and other providers of Internet services to end-users. It operates in three segments: Ting, Wavelo, and Tucows Domains. It generates the majority of its revenue from Tucows Domains. The company generates key revenue from Canada and USA.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.